Figure 3From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsTime to first event (occurrence of any component of the 4P-MACE composite) for patients receiving linagliptin versus placebo.Back to article page